Global dissemination of FC-ϵ RI and p53 signalling perturbation contribute to Dasatinib resistance in Pancreatic Cancer Cell-lines

Abstract

Acquired Dasatinib Resistance (ADR) hinders efficacious treatment of Pancreatic Cancer (PC), often mediated by dynamic signalling reprogramming due to prolonged drug intake. With a novel signalling cross-talk network modelling, this study analyses transcriptomics data of dasatinib-resistant and dasatinib-sensitive pancreatic cancer cell lines and prioritizes key signalling molecules via systemic coordination of their magnitude of dysregulation and the degree of signalling cross-talk among enriched pathways. Results found the p53 and FC-{epsilon} RI signalling pathways demonstrating significant perturbation enrichment, complementarily orchestrating a total of 87% of the global perturbation map in dasatinib resistance. Further statistical characterization of the cross-talk network identified 10 key resistant biomarkers, including THBS1, CDKN1A, and BCL2L1 within p53 signalling, and RAC2 and MAPK13 within FC epsilon RI signalling. Validation with TCGA transcriptomics, CPTAC relative proteomics, and StringDB protein-protein interaction data for their potential prognostics revealed BCL2L1 as pivotal for global perturbation dissemination and, thereby, a novel therapeutic target.